Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Genomics PLC is currently managing a portfolio in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This 1 pending office action is assigned to 1 distinct art unit, indicating a concentrated technical focus for the current patent activities. Practitioners should prioritize understanding the specific examination standards and technical precedents of this 1 distinct art unit to navigate the prosecution effectively. The concentration of the portfolio within 1 distinct art unit allows for a highly targeted legal strategy that addresses the specific requirements of that technical group.
The prosecution of this portfolio is handled by 1 distinct examiner, THOMPSON, MILANA KAYE, who is also the busiest examiner with 1 pending office action. Because THOMPSON, MILANA KAYE is the only official involved in the current pending matters, the success of the portfolio depends on a productive relationship with this individual. Practitioners should carefully review the past decisions and preferences of THOMPSON, MILANA KAYE to optimize their response to the 1 pending office action. This concentrated prosecution environment simplifies the management of the 1 pending office action, as there are no competing examiner styles to consider within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| THOMPSON, MILANA KAYE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255245 | COMPUTER-IMPLEMENTED METHOD AND APPARATUS FOR ANALYSING GENETIC DATA | THOMPSON, MILANA KAYE | — |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18255245 | COMPUTER-IMPLEMENTED METHOD AND APPARATUS FOR ANALYSING GENETIC DATA | THOMPSON, MILANA KAYE | 1687 | §103DP | Non-Final OA | — | Pending | May 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenomics PLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Milana Kaye Thompson has the most, with 1 of Genomics PLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
